GOS prebiotic gains regulatory path to medical foods in Europe
The listing for galactooligosaccharides in the European Union’s list of Novel Foods now mentions Foods for Special Medical Purposes (FSMPs).
Prebiotic ingredient galactooligosaccharides (GOS) is strengthening its position in the medical food industry in the European Union. The listing for galactooligosaccharides in the European Union’s list of approved Novel Foods now includes Foods for Special Medical Purposes (FSMPs).
The news was shared by UK-based prebiotics supplier Clasado Biosciences, which together with European FSMP producer GLNP Life Sciences submitted the petition to the European Food Safety Authority (EFSA). The companies’ press release reports: “Following a positive opinion from the European Food Safety Authority (EFSA) earlier this year, the European Commission, which oversees the Union list of Novel Foods, has now updated the entry for galactooligosaccharides (GOS) with the addition of FSMPs.”
In the press release, Lucie Nagy, Clasado general counsel, stated, “The amendment of the GOS entry in the Union List of Novel Foods to include Foods for Special Medical Purposes (FSMPs) unlocks more possibilities for nutrition-based healthcare product formulators.”
In the medical foods market, prebiotic GOS has the potential to support impaired gastrointestinal issues in hospitalized patients, the companies add.
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
Recent study compares the effectiveness of two probiotic products on colicky infants
October 31st 2024The study compared AB-Biotics and Kaneka Probiotics’ probiotic formulation of Bifidobacterium longum KABP®-042 and Pediococcus pentosaceus KABP®-041 to Lactobacillus reuteri DSM17938 (LR) from Biogaia.
